Latest Headlines

  1. IBM Quantum Computer Accurately Simulates Real Magnetic Materials, Reproducing National Laboratory Data 3/26/2026

    IBM (NYSE: IBM) today announced new results that its quantum computer can simulate real magnetic materials with results that match neutron scattering experiments, marking a significant step towards using quantum computers as reliable tools for scientific discovery.

  2. SEQSTER Unveils AI-Powered Patient Screening For Clinical Trials 3/26/2026

    SEQSTER PDM, Inc. (“SEQSTER”), the leading healthcare technology company powering the connection, collection, and orchestration layer of patient health data, today launched 1-Click Eligibility, an AI solution that helps research teams identify eligible clinical trial participants in minutes.

  3. Simulations Plus Announces Strategic Collaboration Programs For AI-Enabled Modeling 3/26/2026

    Simulations Plus, Inc. (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug development lifecycle.

  4. Hoth Therapeutics Deploys OpenClaw™ AI Platform To Accelerate Drug Discovery 3/26/2026

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced the deployment of OpenClaw™, an advanced AI-enabled computational platform designed to accelerate drug discovery, enhance data-driven decision-making, and unlock value across its therapeutic pipeline.

  5. Purple Biotech Announces AI Collaboration With Converge Bio To Accelerate Development Of Its Next-Generation Tri-Specific Antibody Platform 3/25/2026

    Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced a collaboration with Converge Bio, a company known for its leading AI platform for drug discovery and development, to accelerate and enhance Purple Biotech’s next-generation tri-specific antibody platform leveraging advanced generative AI capabilities.

  6. Xtressé™ Announces FDA IND Acceptance For Xvie, The First & Only Extracellular Vesicle Injectable Therapy For Androgenetic Alopecia 3/24/2026

    Xtressé™, the advanced hair health company founded by dermatologists and scientists, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for Xvie, a regenerative therapy for androgenetic alopecia.

  7. Insilico Medicine And ASKA Pharmaceutical Expand Partnership To Discover Novel Targets For Women's Health 3/24/2026

    Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. ("ASKA"), a specialized pharmaceutical company with a strong focus on internal medicine, obstetrics, and gynecology.

  8. Kelun-Biotech Receives IND Approval For SKB103, A Novel TAA-PD-L1 Bispecific ADC 3/24/2026

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined Tumor-Associated Antigen-targeting and Immuno-Oncology mechanisms (TAA-PD-L1 bsADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors.

  9. Quotient Therapeutics Announces Collaboration With Merck To Discover Novel Drug Targets In Inflammatory Bowel Disease Using Somatic Genomics Platform Technology 3/24/2026

    Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration agreement with Merck, known as MSD outside the US and Canada, to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient’s somatic genomics platform technology.

  10. Sinopia Biosciences Awarded NCI Grant To Advance LEADS Drug Discovery Platform For Oncology 3/24/2026

    Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS (LEarn And DiScover) drug discovery platform, today announced it has been awarded a research grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to expand the application of its metabolomics-driven discovery capabilities to oncology.